Platinum-Gemcitabine-Avastin (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

Trial Profile

Platinum-Gemcitabine-Avastin (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Carboplatin; Cisplatin; Oxaliplatin
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms PGA
  • Most Recent Events

    • 25 Sep 2017 Status changed from recruiting to discontinued.
    • 20 Jan 2015 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016, as reported by ClinicalTrials.gov.
    • 20 Jan 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top